Endocrine Disruption Screening Market Size, Trends and Growth Analysis by 2027

The global market for endocrine disruption screening is anticipated to grow significantly, reaching an estimated US$ 153.30 million by 2028, up from US$ 126.53 million in 2021. This growth represents a compound annual growth rate (CAGR) of 2.8% from 2021 to 2028.

This report outlines the prevailing trends within the market and identifies key factors contributing to its expansion. The growth of the market is primarily driven by the increasing incidence of endocrine disorders and a notable rise in diabetes cases. However, the high costs associated with screening technologies pose a challenge to market growth.

The escalating number of cancer patients, particularly those with hormone-related cancers, is expected to boost the demand for endocrine disruption screening globally. According to the National Institute of Cancer, as of January 2019, there were approximately 16.9 million cancer survivors in the United States, with projections indicating this number could rise to 22.2 million by 2030. The most frequently diagnosed cancers in the US include breast cancer, thyroid cancer, prostate cancer, colon and rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, pancreatic cancer, and bladder cancer. Notably, breast cancer was the most prevalent in 2021, with 284,200 new cases, followed by prostate and lung cancers.

Many companies are focusing on developing markets such as India and China, where large populations are affected by chronic diseases. As production costs rise, healthcare companies are under pressure to generate sufficient revenue to satisfy their investors. Advances in biotechnology have spurred demand for diagnostics in the healthcare sector, leading to the introduction of innovative analytical systems and promoting a shift towards personalized medicine. Emerging opportunities are particularly evident in areas such as infectious disease testing, molecular oncology, and pharmacogenomics in developing nations.

The global endocrine disruption screening market is categorized by assay type into in-vitro and in-vivo methods. The in-vitro segment dominated the market in 2021 and is projected to experience a higher CAGR during the forecast period. In terms of application, the market is divided into natural materials and synthetic materials, with the natural materials segment holding a larger market share in 2021 and expected to grow at a faster CAGR of 3.1% from 2021 to 2028.

When considering the sources of waste, the market is segmented into incineration and landfill, agricultural runoff, industrial and municipal effluents, pulp mill effluents, consumer products, and others. The incineration and landfill segment was the largest in 2021 and is projected to grow at the fastest CAGR of 3.5% from 2021 to 2028.

Furthermore, the market is segmented by method into various categories, including estrogen receptor (ER) transactivation, androgen receptor (AR) transactivation, androgen receptor (AR) modulation, estrogen receptor-alpha (ER) binding, estrogen receptor beta (ER) binding, androgen receptor (AR) binding, steroidogenesis, aromatase assay, and others. The estrogen receptor (ER) transactivation segment held the largest market share in 2021 and is expected to grow at the fastest CAGR of 3.7% during the forecast period.

By end user, the market is divided into segments such as pharmaceutical and biopharmaceutical companies, cosmetics and household product companies, the food industry, and the chemical industry. In 2021, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the market and is projected to grow at a CAGR of 3.3% from 2021 to 2028.

Key sources referenced in the preparation of this report include reputable organizations such as the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), and the National Institute of Cancer.